Share Capital (Details) - Schedule of Outstanding Warrants - USD ($) |
12 Months Ended | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2023 |
Dec. 31, 2022 |
|||||||||||
| Share Capital (Details) - Schedule of Outstanding Warrants [Line Items] | ||||||||||||
| Outstanding | $ 40,117,204 | $ 28,403,734 | ||||||||||
| Issuance year | 3 years 6 months 10 days | 4 years | ||||||||||
| Warrant [Member] | ||||||||||||
| Share Capital (Details) - Schedule of Outstanding Warrants [Line Items] | ||||||||||||
| Outstanding | $ 117,209 | [1] | $ 117,209 | [2] | ||||||||
| Issuance year | 2009 years | [1] | 2009 years | [2] | ||||||||
| Exercise price | [3] | [1] | [2] | |||||||||
| Exercisable through | Exit event | [1] | Exit event | [2] | ||||||||
| Warrant One [Member] | ||||||||||||
| Share Capital (Details) - Schedule of Outstanding Warrants [Line Items] | ||||||||||||
| Outstanding | $ 28,571,425 | $ 59,384 | [2] | |||||||||
| Issuance year | 2022 years | 2013 years | [2] | |||||||||
| Exercise price | $ 0.07 | $ 0.92 | [2] | |||||||||
| Exercisable through | 2024(***) | [4] | 2023 | [2] | ||||||||
| Warrant Two [Member] | ||||||||||||
| Share Capital (Details) - Schedule of Outstanding Warrants [Line Items] | ||||||||||||
| Outstanding | $ 11,428,570 | $ 170,000 | [2] | |||||||||
| Issuance year | 2023 years | 2018 years | [2] | |||||||||
| Exercise price | $ 0.07 | $ 0.5 | [2] | |||||||||
| Exercisable through | 2025 | 2023 | [2] | |||||||||
| Warrant Three [Member] | ||||||||||||
| Share Capital (Details) - Schedule of Outstanding Warrants [Line Items] | ||||||||||||
| Outstanding | [2] | $ 200,001 | ||||||||||
| Issuance year | [2] | 2018 years | ||||||||||
| Exercise price | [2] | $ 0.5 | ||||||||||
| Exercisable through | [2] | 2023 | ||||||||||
| Warrant Four [Member] | ||||||||||||
| Share Capital (Details) - Schedule of Outstanding Warrants [Line Items] | ||||||||||||
| Outstanding | $ 27,857,140 | |||||||||||
| Issuance year | 2022 years | |||||||||||
| Exercise price | $ 0.07 | |||||||||||
| Exercisable through | [4] | 2024(***) | ||||||||||
| ||||||||||||